Abstract 10606: Blood Pressure Reduction With Dapagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

Background: Dapagliflozin (DAPA) is a selective SGLT2 inhibitor shown to reduce hyperglycemia and weight in patients with type 2 diabetes mellitus (T2DM). DAPA has demonstrated efficacy as monotherapy or combined with oral antidiabetic drugs and/or insulin. The clinical effect of DAPA, which has mild osmotic diuretic properties, on systolic blood pressure (SBP) was analyzed in 2 trials (Study [ST] 1: NCT01031680, N=922; ST2: NCT01042977, N=964) of DAPA vs placebo (PBO) added to usual care in T2DM patients with established cardiovascular disease (CVD). Glycemic efficacy and overall safety in these studies have been reported. Methods: Patients received DAPA 10 mg (ST1: n=460; ST2: n=482) or PBO (ST1: n=462; ST2: n=483) added to stable antidiabetic and antihypertensive (AHT) background medication. We conducted prespecified and post-hoc analyses of SBP-related measures comparing treatment groups overall and in predefined age strata (<65 and ≥65 y). Data following changes in AHT medications were excluded. Resu...